Oncology

Latest News

Innovation vs Affordability: Cancer Care’s Cost Crisis and Access Gap
Innovation vs Affordability: Cancer Care’s Cost Crisis and Access Gap

August 21st 2025

RIsing costs for therapies and inequities in reimbursement for genomic testing have created financial barriers for patients, according to appearing experts in Detroit, Michigan, on July 10, 2025.

The investigators found that tumor mutational burden and PD-L1 expression, which have traditionally been used as indicators of immunotherapy efficacy, had little predictive value for survival in this cohort. | Image credit: Dragana Gordic - stock.adobe.com
Predictive Model Forecasts Advanced NSCLC Outcomes

August 14th 2025

Dordaviprone is indicated for recurrent H3 K27M-mutant diffuse midline glioma, an ultra-rare, aggressive brain tumor primarily affecting children. | Image credit: wladimir1804 - stock.adobe.com
FDA Approves Dordaviprone as First and Only Treatment for Aggressive Form of Glioma

August 6th 2025

Gen Li, PhD, MBA, president and founder of Phesi
Real-World Data, Digital Patient Profiles Are Revolutionizing Trial Design, Patient Recruitment: Gen Li, PhD, MBA

August 4th 2025

Value-based care. | Image Credit: irissca - stock.adobe.com
Legal Navigation Services Key to Addressing Disparities in Cancer Care

July 31st 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations
Continuing Medical Education
View All
August 25th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
August 25th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

Site Logo
September 11th 2018

OneOncology Launches to Enable Better Cancer Care in Communities Across America

Three leading oncology practices unite with partners in technology and finance to announce the launch of OneOncology, a patient-centric, physician-driven, and technology-powered company with a mission to improve the lives of everyone living with cancer.
Prescription Drug Coverage Improved Survival for Patients With MM
September 9th 2018

Prescription Drug Coverage Improved Survival for Patients With MM

Laura Joszt, MA
Patients with multiple myeloma (MM) who are enrolled in a Medicare Part D plan or other creditable prescription drug coverage have better survival than patients without prescription drug coverage. According to a study in Journal of Clinical Oncology, this improved survival seemed to be a result of patients having access to all treatment options.
HIV/AIDS Research Has Positive Impacts Across Other Medical Fields
September 6th 2018

HIV/AIDS Research Has Positive Impacts Across Other Medical Fields

Jaime Rosenberg
In addition to the advances made in the HIV space, such as antiretroviral therapies and pre-exposure prophylaxis, the years of research has translated into advances outside the HIV field, including in oncology and other immune diseases.
Bringing Virtual Tumor Boards, Real-Time Data to the Point of Care
September 5th 2018

Bringing Virtual Tumor Boards, Real-Time Data to the Point of Care

As the oncology landscape continues to rapidly evolve, access to real-time data has become increaisngly important, and technology-based medical startups have made their way to the front of the lines with point-of-care tools that use technology to transform cancer care.
Amgen Seeks Expanded Indication for Once-Weekly Kyprolis for Multiple Myeloma
September 4th 2018

Amgen Seeks Expanded Indication for Once-Weekly Kyprolis for Multiple Myeloma

Laura Joszt, MA
Amgen has submitted a supplemental New Drug Application to the FDA to expand the prescribing information of carfilzomib (Kyprolis) to include a once-weekly dosing option in combination with dexamethasone for patients with relapsed or refractory multiple myeloma.
Lay Health Workers May Provide Value for Patients With Cancer in New Payment Models
September 2nd 2018

Lay Health Workers May Provide Value for Patients With Cancer in New Payment Models

Laura Joszt, MA
As the healthcare system considers alternative payment models that reward high-value care delivery, programs that utilize lay health workers (LHW) may be valuable. A study in JAMA Oncology analyzed whether an LHW program can increase the documentation of patients’ care preferences.
What We're Reading: Calif. Drug Price Lawsuit Tossed; Testing ARBs for Cancer Link; Hope for Nonaddictive Painkiller
August 31st 2018

What We're Reading: Calif. Drug Price Lawsuit Tossed; Testing ARBs for Cancer Link; Hope for Nonaddictive Painkiller

AJMC Staff
A judge tossed a lawsuit brought by pharmaceutical companies to block a California law requiring advance notice of big price increases; the FDA is testing all angiotensin II receptor blockers (ARBs) over a discovered impurity that is linked to cancer; research in monkeys has suggested that an experimental painkiller is effective at easing pain without being addictive.
Dr Don Dizon: Discussing Sexual Health Needs With Patients With Cancer
August 31st 2018

Dr Don Dizon: Discussing Sexual Health Needs With Patients With Cancer

Most oncologists aren’t comfortable discussing sexual health needs with their patients, but there are places where sexual health services for patients with cancer are starting to gain foothold, said Don S. Dizon, MD, FACP, FASCO, director of Women's Cancers at the Lifespan Cancer Institute, director of medical oncology at Rhode Island Hospital, and associate professor of medicine at The Warren Alpert Medical School of Brown University.
Patients With Blood Cancer Less Likely to Understand Diagnosis Compared With Other Cancers
August 31st 2018

Patients With Blood Cancer Less Likely to Understand Diagnosis Compared With Other Cancers

Laura Joszt, MA
A survey of patients in the United Kingdom who were diagnosed with cancer found that patients with blood cancers were the least likely to say they completely understood what was wrong when the doctor explained it. They were also less likely to say that their treatment options were explained before treatment started compared with patients with other cancers.
Site Logo
August 30th 2018

Medicaid Expansion Helped Reduce Disparities Among Different Groups With Cancer

Allison Inserro
The expansion of Medicaid may mitigate health disparities in cancer diagnosis, according to a recent study that found state variation in reductions in the percentage of uninsured patients aged 18 to 64 years diagnosed with cancer. The researchers said that the results have implications for future disparities in state mortality rates, because health insurance coverage is linked to the ability to have better treatment and survival after diagnosis.
Childbirth Rates for Female Survivors of Hodgkin Lymphoma Similar to General Population
August 28th 2018

Childbirth Rates for Female Survivors of Hodgkin Lymphoma Similar to General Population

Laura Joszt, MA
As cure rates for young patients with Hodgkin lymphoma (HL) improve, the historically negative impact of treatments has to be considered. However, a new study has found that over time, childbearing rates for female survivors of HL have improved to the point of approaching the rates of the general population.
Podcast: This Week in Managed Care—Patient-Reported Outcomes With CAR T and Other Health News
August 25th 2018

Podcast: This Week in Managed Care—Patient-Reported Outcomes With CAR T and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
Utilizing Bioinformatics to Determine a Patient's Response to Immunotherapy
August 24th 2018

Utilizing Bioinformatics to Determine a Patient's Response to Immunotherapy

Samantha DiGrande
A recent study at Johns Hopkins Bloomberg-Kimmel Institute for Cancer Immunotherapy discovered a new way to use bioinformatics to determine how a patient’s immune system responds to immunotherapy.
This Week in Managed Care: August 24, 2018
August 24th 2018

This Week in Managed Care: August 24, 2018

This week, the top managed care news included a panel mostly endorsed the use of patient-reported outcomes for coverage of chimeric antigen receptor T-cell therapy; the US Preventive Services Task Force released new recommendations for cervical cancer screening; research found accountable care organization penetration may be changing how physicians work.
NCCN Releases New Guidelines for Rare Cancers During Pregnancy
August 23rd 2018

NCCN Releases New Guidelines for Rare Cancers During Pregnancy

Samantha DiGrande
Earlier this month, the National Comprehensive Cancer Network (NCCN) released new treatment guidelines for a group of rare cancers that impact women during pregnancy.
Site Logo
August 23rd 2018

CURE Media Group Expands Strategic Alliance Partnership Program With The Biden Cancer Initiative

Sister publication American Journal of Managed Care® will also be a part of this collaboration.
Tracking ctDNA Levels Can Quickly Predict Response to Lymphoma Therapy
August 22nd 2018

Tracking ctDNA Levels Can Quickly Predict Response to Lymphoma Therapy

Laura Joszt, MA
A blood test that tracks the rise and fall of circulating tumor DNA (ctDNA) levels can predict how patients with diffuse large B-cell lymphoma will respond to therapy within days of starting treatment.
Dr Denalee O'Malley Discusses Unique Concerns of Younger Patients With Breast Cancer
August 22nd 2018

Dr Denalee O'Malley Discusses Unique Concerns of Younger Patients With Breast Cancer

Younger, premenopausal patients with breast cancer can have unique issues that providers need to keep in mind, said Denalee O’Malley, PhD, LSW, instructor, Department of Family Medicine and Community Health, Rutgers Robert Wood Johnson Medical School.
Site Logo
August 22nd 2018

From the Editor-in-Chief: What Happens Next?

Joseph Alvarnas, MD
A letter from our Editor-in-Chief, Joseph Alvarnas, MD.
Site Logo
August 22nd 2018

Survivorship Care Throughout the Cancer Journey

Don Champlain, MHA, RN Lucio Gordan, MD
Leaders at Florida Cancer Specialists discuss the cancer survivorship program they've created to meet the needs of their diverse population of patients.
Site Logo
August 22nd 2018

Conference Coverage: NCCN Policy Summit 2018

Mary Caffrey
Site Logo
August 22nd 2018

AJMCtv® Interviews, August 2018

Mary Caffrey Jaime Rosenberg Samantha DiGrande
Site Logo
August 22nd 2018

Clinical Updates, August 2018

Surabhi Dangi-Garimella, PhD Laura Joszt, MA Kelly Davio Samantha DiGrande
Site Logo
August 21st 2018

EBO 2018: Managed Care Updates

Jaime Rosenberg Laura Joszt, MA Alison Rodriguez
CAR T Signaling Differences Could Point the Way to More Targeted Treatments, Study Says
August 21st 2018

CAR T Signaling Differences Could Point the Way to More Targeted Treatments, Study Says

Allison Inserro
The first chimeric antigen receptor (CAR) T-cell therapy was approved just a year ago, changing the face of treatment for certain types of leukemias and lymphomas but carrying with it the downsides of toxicity and cost. A year later, scientists from a major cancer center said that they’ve made headway to discovering more about the T-cell signaling patterns and that understanding more about the biological pathways could help design the next generation of CAR-T treatments.
Payment Reform in Cancer Needs to Engage and Reward Patients, Experts Assert
August 21st 2018

Payment Reform in Cancer Needs to Engage and Reward Patients, Experts Assert

Laura Joszt, MA
Payment reform efforts that don't engage patients are missing out on an opportunity for greater improvements, especially in cancer, where patients face substantial cost sharing.
Site Logo
August 20th 2018

Economic Evaluation of Patient-Centered Care Among Long-Term Cancer Survivors

Jaejin An, BPharm, PhD Adrian Lau, PharmD
Providing patient-centered comprehensive care to long-term cancer survivors may lead to reduced total healthcare expenditures. Check out our website’s new table/figure pop-up feature! Click on the name of a table or figure in the text to see it in your browser.
Site Logo
August 17th 2018

Many Questions to Ask in Setting National Coverage for CAR T Therapies

Allison Inserro
Next week, a CMS committee will hold a day-long meeting to discuss a national coverage determination (NCD) for chimeric antigen receptor (CAR) T-cell immunotherapies, and in Thursday’s New England Journal of Medicine, Peter B. Bach, MD, MAPP, reviewed several strategies open to CMS as it continues to try to determine how to pay for CAR T.
PARP Inhibitor Increases PFS Over Chemotherapy in Advanced Breast Cancers, Study Finds
August 16th 2018

PARP Inhibitor Increases PFS Over Chemotherapy in Advanced Breast Cancers, Study Finds

Samantha DiGrande
A recent study found that the poly (ADP-ribose) polymerase (PARP) inhibitor talazoparib extended progression-free survival (PFS) and improved quality of life over chemotherapies for patients with metastatic human epidermal growth factor 2-negative breast cancer and mutations in the BRCA 1/2 genes.
AI Platform Can Identify Personalized Drug Combinations to Treat Multiple Myeloma
August 16th 2018

AI Platform Can Identify Personalized Drug Combinations to Treat Multiple Myeloma

Laura Joszt, MA
A new technology platform utilizing artificial intelligence (AI) could change how drug combinations are designed and help doctors to identify optimal personalized drug combinations for patients with multiple myeloma.
<1
...
414243444546474849
...
187>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo